Microdosing semaglutide means taking less than the label's doses, often much less. The reasons given are cost, gentler side effects, or wanting to lose only a little weight. [4]
There is no agreed definition of the word, and no trial has tested it. What you can check is what trials found at lower doses, and what the label says about going slower.
What people mean by microdosing
A 2026 brief report for nurse practitioners described the practice from the clinic side [4]. It named two drivers: stomach side effects, and wanting to lose a small amount of weight.
The same report listed the risks it saw. Those included dosing errors, tampering with pens, compounded vials and people sharing medicine. It called microdosing a subtherapeutic, unsupervised strategy.
A search of PubMed for semaglutide microdosing finds commentary and reviews. It does not find a trial of the practice.
The closest evidence: a trial that started very low
The best look at small doses comes from a phase 2 trial run before Wegovy was approved [2]. It enrolled 957 adults with obesity and without diabetes, for 52 weeks.
Semaglutide was injected once a day, not once a week. Daily doses ran from 0.05 mg to 0.4 mg, and everyone also received diet and activity counseling.
One group got liraglutide, an older daily drug, as a comparison. How the two drugs differ is set out in liraglutide vs semaglutide.
| Daily dose | Mean weight change |
|---|---|
| Placebo | -2.3% |
| 0.05 mg | -6.0% |
| 0.1 mg | -8.6% |
| 0.2 mg | -11.6% |
| 0.3 mg | -11.2% |
| 0.4 mg | -13.8% |
| Liraglutide 3.0 mg (comparison) | -7.8% |
So the smallest dose did beat placebo. It also delivered well under half the loss of the top dose. A daily 0.05 mg adds up to 0.35 mg a week, by simple multiplication. That is a little above the Wegovy starting dose of 0.25 mg.
The side effects followed the dose too. The authors reported that the most common adverse events were dose-related stomach symptoms, mainly nausea.
A lower dose is not a side-effect-free dose
STEP 2 gave adults with overweight and type 2 diabetes either 2.4 mg, 1.0 mg or placebo once a week, for 68 weeks [3]. The 1.0 mg dose was the diabetes dose at the time.
Stomach and bowel side effects affected 63.5% on 2.4 mg and 57.5% on 1.0 mg. On placebo the figure was 34.3%.
Cutting the dose by more than half removed only a small share of those effects. That trial did not test doses far below 1.0 mg, so it cannot say what happens at microdoses.
What the label already does
The Wegovy label starts everyone at 0.25 mg a week for 4 weeks [1]. The dose then rises to 0.5 mg, 1 mg and 1.7 mg, each for 4 weeks, before a maintenance dose.
The label says the slow climb is there to reduce stomach side effects. If you do not tolerate a step, it suggests delaying the next increase by 4 weeks.
For weight in adults, the maintenance dose is 1.7 mg or 2.4 mg a week. The label allows a rise to 7.2 mg for people who tolerate 2.4 mg for at least 4 weeks and need more weight loss.
What this means for you
If side effects are the worry, the label already has a slower path. Delaying a step, or staying on 1.7 mg, are options to raise with your prescriber.
If cost is the worry, a smaller dose may also mean less weight lost, as the phase 2 trial showed. The oral form is another route; see the Wegovy pill for what its trials found.
Stopping altogether is its own question, covered in what happens when you stop taking semaglutide. For how side effects compare on the other weekly shot, read tirzepatide side effects. Other options sit on the weight goal page.